The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Open accessAbstract
Cancer cells have metabolic dependencies that distinguish them from their normal counterparts. Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes. Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into α-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [73]
In the citing paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [57]
In the citing paper
“Mouse PDAC tumors driven by mutant Kras also experience metabolic alteration and are dependent on glucose and glutamine (73, 77).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [77]
In the citing paper
“combining inhibition of glycolysis with blockade of KRAS effector signaling pathways has shown efficacy in culture and xenograft models197”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“However, under normal and glucose-replete conditions, transamination is the dominant reaction that drives glutamine anaplerosis in cultured cells (79, 80, 81, 82).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Cited by
Sorted by citations
Items 901–1,000 of 1,004
An integrative theory for cancer (Review)
Luo, G., & Liu, N. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.4004 · Cited by 33
Hypoxic adaptation of mitochondria and its impact on tumor cell function
Benej, M., Papandreou, I., & Denko, N. C. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.004 · Cited by 33
Zhan, B., Shi, W., Lu, J., Shen, G., Lin, X., Feng, J., & Huang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18057 · Cited by 31
Trinidad, A. G., Whalley, N., Rowlinson, R. A., Delpuech, O., Dudley, P., Rooney, C., & Critchlow, S. E. (2017) · Oncogene · doi:10.1038/onc.2017.224 · Cited by 31
Lee, H. Y., Itahana, Y., Schüchner, S., Fukuda, M., Je, H. S., Ogris, E., Virshup, D. M., & Itahana, K. (2018) · Science Signaling · doi:10.1126/scisignal.aam7893 · Cited by 31
Synthetic lethality: a step forward for personalized medicine in cancer
Jariyal, H., Weinberg, F. D., Achreja, A., Nagarath, D., & Srivastava, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.014 · Cited by 30
Architectural control of metabolic plasticity in epithelial cancer cells
Al‐Masri, M., Paliotti, K., Tran, R., Halaoui, R., Lelarge, V., Chatterjee, S. J., Wang, L., Moraes, C., & McCaffrey, L. M. (2021) · Communications Biology · doi:10.1038/s42003-021-01899-4 · Cited by 33
Blachier, J., Cleret, A., Guérin, N., Gil, C., Fanjat, J.-M., Tavernier, F., Vidault, L., Gallix, F., Rama, N., Rossignol, R., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113568 · Cited by 31
Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor
Cheng, L., Wu, C., Zhu, L., Li, H., & Chen, L.-X. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.01.057 · Cited by 31
Xu, K., Ding, J., Zhou, L., Li, D., Luo, J., Wang, W., Shang, M., Lin, B., Zhou, L., & Zheng, S. (2022) · Cells · doi:10.3390/cells12010025 · Cited by 31
Zhang, J., Wei, L., Ma, X., Wang, J., Liang, S., Chen, K., Wu, M., Niu, L., & Zhang, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.040 · Cited by 30
Ren, X., Yan, J., Zhao, Q., Bao, X., Han, X., Chen, Z., Zhou, Y., Chen, L., Wang, B., Yang, L., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00558-8 · Cited by 30
Lee, H. M., Muhammad, N., Lieu, E. L., Cai, F., Mu, J., Ha, Y., Cao, G., Suchors, C., Joves, K., Chronis, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01066-z · Cited by 33
Inducing disulfidptosis in tumors:potential pathways and significance
Mi, T., Kong, X., Chen, M., Guo, P., & He, D. (2024) · MedComm · doi:10.1002/mco2.791 · Cited by 44
Sheikh, T. N., Patwardhan, P. P., Cremers, S., & Schwartz, G. K. (2017) · Oncotarget · doi:10.18632/oncotarget.21573 · Cited by 30
Critical role of KRAS mutation in pancreatic ductal adenocarcinoma
Fan, Z., Fan, K., Yan, C., Huang, Q., Gong, Y., Cheng, H., Jin, K., Liu, C., Ni, Q., Yu, X., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.19 · Cited by 30
Lemberg, K. M., Zhao, L., Wu, Y., Veeravalli, V., Alt, J., Aguilar, J. M. H., Dash, R. P., Lam, J., Tenora, L., Rodriguez, C., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0319 · Cited by 28
Soumoy, L., Schepkens, C., Krayem, M., Najem, A., Tagliatti, V., Ghanem, G., Saussez, S., Colet, J., & Journé, F. (2020) · Cancers · doi:10.3390/cancers12051323 · Cited by 30
Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth
Contat, C., Ancey, P., Zangger, N., Sabatino, S., Pascual, J., Escrig, S., Jensen, L. H. S., Goepfert, C., Lanz, B., Lepore, M. G., et al. (2020) · eLife · doi:10.7554/elife.53618 · Cited by 30
Amrutkar, M., & Gladhaug, I. P. (2021) · Cancers · doi:10.3390/cancers13040601 · Cited by 31
Guo, Y., Wang, R., Li, J., Song, Y., Min, J., Zhao, T., Hua, L., Shi, J., Zhang, C., Ma, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.769425 · Cited by 30
GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma
Feld, F. M., Nagel, P. D., Weissinger, S. E., Welke, C., Stenzinger, A., Möller, P., & Lennerz, J. K. (2015) · Oncotarget · doi:10.18632/oncotarget.2799 · Cited by 30
Phua, L. C., Goh, S., Tai, D. W. M., Leow, W. Q., Alkaff, S. M. F., Chan, C. Y., Kam, J. H., Lim, T. K. H., & Chan, E. C. Y. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3475-6 · Cited by 31
Yi, Y., Peng, Z., Liu, Y., Hao, H., Liu, Y., Wen, S., Sun, S., Shi, J., Wu, M., & Mei, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.020 · Cited by 29
Do, L. K., Lee, H. M., Ha, Y., Lee, C., & Kim, J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115529 · Cited by 38
Søreide, K., & Sund, M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.028 · Cited by 29
Zhou, X., Zheng, W., Gowda, G. A. N., Raftery, D., Donkin, S. S., Bequette, B. J., & Teegarden, D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.022 · Cited by 28
Glutaminase inhibitors: a patent review
Wu, C., Chen, L., Jin, S., & Li, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1530759 · Cited by 29
Zhong, J., Yu, Q., Zhou, S., Yu, E., Bao, Y., Lu, Z., & Fan, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221423 · Cited by 28
HBXIP Regulates Gastric Cancer Glucose Metabolism and Malignancy Through PI3K/AKT and p53 Signaling
Qiu, L., Lu, F., Zhang, L., Wang, G., Geng, R., & Miao, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s243250 · Cited by 29
The SLC7A11: sperm mitochondrial function and non-canonical glutamate metabolism
Ortiz-Rodriguez, J. M., Martín‐Cano, F. E., Gaitskell‐Phillips, G., Silva, A., Tapia, J. A., Gil, M. C., Redondo, E., Masot, J., Ortega‐Ferrusola, C., & Peña, F. J. (2020) · Reproduction · doi:10.1530/rep-20-0181 · Cited by 29
Asiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 29
Targeting autophagy as a therapeutic strategy against pancreatic cancer
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01889-1 · Cited by 29
Autophagic lipid metabolism sustains mTORC1 activity in TSC-deficient neural stem cells
Wang, C., Haas, M. A., Yang, F., Yeo, S. K., Okamoto, T., Chen, S., Wen, J., Sarma, P., Plas, D. R., & Guan, J. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0137-5 · Cited by 29
Diagnostic Value of Salivary Amino Acid Levels in Cancer
Bel’skaya, L. V., Sarf, E. A., & Loginova, A. I. (2023) · Metabolites · doi:10.3390/metabo13080950 · Cited by 28
Emerging trends of phytochemicals as ferroptosis modulators in cancer therapy
Khan, F., Pandey, P., Verma, M., Ramniwas, S., Lee, D., Moon, S., Park, M. N., Upadhyay, T. K., & Kim, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116363 · Cited by 29
Hu, S., Heng, H., Yang, F., Wang, M., Liu, G., Xiang, Y., & Miao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1735873 · Cited by 32
Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge
Rizwani, W., Allen, A., & Trevino, J. G. (2015) · Cancers · doi:10.3390/cancers7030861 · Cited by 28
PARP and other prospective targets for poisoning cancer cell metabolism
Michels, J., Obrist, F., Castedo, M., Vitale, I., & Kroemer, G. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.026 · Cited by 28
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze
Olivares, O., & Vasseur, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29501 · Cited by 28
Breitkopf, S. B., Yuan, M., Helenius, K., Lyssiotis, C. A., & Asara, J. M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03040 · Cited by 27
Self-citationIKKβ activates p53 to promote cancer cell adaptation to glutamine deprivation
Gabra, M. B. I., Yang, Y., Lowman, X. H., Reid, M. A., Tran, T. Q., & Kong, M. (2018) · Oncogenesis · doi:10.1038/s41389-018-0104-0 · Cited by 29
Thu, P. M., Zheng, Z., Zhou, Y., Wang, Y., Zhang, X., Jing, D., Cheng, H.-M., Li, J., Li, P., & Xu, X. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.060 · Cited by 28
Ishikawa, K., Hosoi, Y., Tanaka, H., Jiang, L., Toyokuni, S., Nakamura, K., Kajiyama, H., Kikkawa, F., Mizuno, M., & Hori, M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108414 · Cited by 28
Hipólito, A., Nunes, S. C., Vicente, J. B., & Serpa, J. (2020) · Molecules · doi:10.3390/molecules25173984 · Cited by 30
Zhou, W.-X., Chen, C., Liu, X., Li, Y., Lin, Y., Wu, X.-T., Kong, L., & Luo, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112980 · Cited by 28
Kundu, S., Ali, M. A., Handin, N., Conway, L. P., Rendo, V., Artursson, P., He, L., Globisch, D., & Sjöblom, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02025-2 · Cited by 31
Metabolic landscapes in sarcomas
MIALLOT, R., Galland, F., Millet, V., Blay, J., & Naquet, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01125-y · Cited by 29
More Than Meets the Eye Regarding Cancer Metabolism
Kubicka, A., Matczak, K., & Łabieniec-Watała, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179507 · Cited by 31
Krysztofiak, A., Szymonowicz, K., Hlouschek, J., Xiang, K., Waterkamp, C., Larafa, S., Goetting, I., Vega-Rubín-de-Celis, S., Theiß, C., Matschke, V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103366 · Cited by 29
Zhou, Y.-J., Yu, H., Cheng, S., Chen, Y., He, L., Ren, J., He, X. Q., Chen, J., Zheng, L., Li, F., et al. (2022) · Journal of Cancer · doi:10.7150/jca.64195 · Cited by 28
Zhong, H., Liu, S., Zhu, J., Xu, T. H., Yu, H., & Wu, L. (2023) · International Journal of Cancer · doi:10.1002/ijc.34771 · Cited by 29
Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment
Wu, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_7 · Cited by 27
Hanada, K., Kawada, K., Nishikawa, G., Toda, K., Maekawa, H., Nishikawa, Y., Masui, H., Hirata, W., Okamoto, M., Kiyasu, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.023 · Cited by 27
The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
Ganjoo, S., Gupta, P., Corbali, H. I., Nanez, S., Riad, T. S., Duong, L. K., Barsoumian, H. B., Masrorpour, F., Jiang, H., Welsh, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172931 · Cited by 32
Koay, E. J., Amer, A. M., Baio, F. E., Ondari, A., & Fleming, J. B. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.006 · Cited by 27
Self-citationPancreatic cancer from bench to bedside: molecular pathways and treatment options
Kosmidis, C. S., Sapalidis, K. G., Kotidis, E. V., Mixalopoulos, N., Zarogoulidis, P., Tsavlis, D., Baka, S., Man, Y.-G., & Kanellos, J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.11 · Cited by 26
Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil
Hong, C., Zheng, J., & Li, X. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3282-0 · Cited by 27
Gong, L., Zhang, D., Lei, Y., Qian, Y., Tan, X., & Han, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1836 · Cited by 28
Li, Y., Li, T., Jin, Y., & Shen, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108950 · Cited by 27
Vesiclemia: counting on extracellular vesicles for glioblastoma patients
Sabbagh, Q., André‐Grégoire, G., Guével, L., & Gavard, J. (2020) · Oncogene · doi:10.1038/s41388-020-01420-x · Cited by 27
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
Pallett, L. J., Dimeloe, S., Sinclair, L. V., Byrne, A. J., & Schurich, A. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab010 · Cited by 28
Structural and functional analysis of disease-associated mutations in GOT1 gene: An in silico study
Saxena, S., Sai Achyuth, B., Murthy, T. P. K., Chandramohan, V., Yadav, A. K., & Singh, T. R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104695 · Cited by 27
Ren, J., Ren, B., Liu, X., Cui, M., Fang, Y., Wang, X., Zhou, F., Gu, M., Xiao, R., Bai, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216649 · Cited by 30
Self-citationZhao, X., Wang, X., Zhang, W., Tian, T., Zhang, J., Wang, J., Wei, W., Guo, Z., Zhao, J., & Wang, X. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202400829 · Cited by 27
Self-citationDealing with hunger: Metabolic stress responses in tumors
Kong, M., & Reid, M. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.119111 · Cited by 30
Metabolomic identification of novel biomarkers of nasopharyngeal carcinoma
Yi, L., Dong, N., Shi, S., Deng, B., Yun, Y., Yi, Z., & Zhang, Y. (2014) · RSC Advances · doi:10.1039/c4ra09860a · Cited by 27
Extracellular acidification stimulates GPR68 mediated IL-8 production in human pancreatic β cells
Chandra, V., Karamitri, A., Richards, P., Cormier, F., Ramond, C., Jockers, R., Armanet, M., Albagli, O., & Scharfmann, R. (2016) · Scientific Reports · doi:10.1038/srep25765 · Cited by 27
Ornelas, A., McCullough, C., Lü, Z., Zacharias, N. M., Kelderhouse, L. E., Gray, J. P., Yang, H., Engel, B. J., Wang, Y., Mao, W., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2850-8 · Cited by 27
LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei
Tseng, Y.-T., Kumar, R., & Wang, H. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.02.035 · Cited by 27
Milković, L., Tomljanović, M., Gašparović, A. Č., Kujundžić, R. N., Šimunić, D., Konjevoda, P., Mojzeš, A., Đaković, N., Žarković, N., & Gall‐Tros̆elj, K. (2019) · Cells · doi:10.3390/cells8091001 · Cited by 27
Julovi, S. M., Xue, A., LE, T. N. T., Gill, A. J., Bulanadi, J. C., Patel, M., Waddington, L. J., Rye, K., Moghaddam, M. J., & Smith, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151475 · Cited by 27
Muranaka, H., Akinsola, R., Billet, S., Pandol, S. J., Hendifar, A. E., Bhowmick, N. A., & Gong, J. (2024) · Cancers · doi:10.3390/cancers16051057 · Cited by 27
Yoo, Y. A., Quan, S., Yang, W., Guo, Q., Rodríguez, Y., Chalmers, Z. R., Dufficy, M. F., Lackie, B., Sagar, V., Unno, K., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2910 · Cited by 26
Metabolic Signaling in the Tumor Microenvironment
Clay, R., Li, K., & Jin, L. (2025) · Cancers · doi:10.3390/cancers17010155 · Cited by 31
Nonhistone lactylation: A hub for tumour metabolic reprogramming and epigenetic regulation
Zhang, D., Liang, C., Wu, C., Hawanga, M., Wan, S., Xu, L., Zhang, X., Liu, Y., Hu, F., Wang, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06813-8 · Cited by 28
Self-citationAziz, A. U. R., Farid, S., Qin, K., Wang, H., & Liu, B. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1498903 · Cited by 28
Xu, J., Khoury, N., Jackson, C. W., Escobar, I., Stegelmann, S. D., Dave, K. R., & Pérez‐Pinzón, M. A. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00729-4 · Cited by 26
Cheng, Z., Dai, Y., Zeng, T., Liu, Y., Cui, L., Qian, T., Si, C., Huang, W., Pang, Y. K., Xu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00379 · Cited by 26
Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Suzuki, T., Kishikawa, T., Sato, T., Takeda, N., Sugiura, Y., Seimiya, T., Sekiba, K., Ohno, M., Iwata, T., Ishibashi, R., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00326-4 · Cited by 28
Zhao, H., Wu, W., Li, X., & Chen, W. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101340 · Cited by 26
Zhao, Y., Wang, Y., Miao, Z., Liu, Y., & Yang, Q. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08495-1 · Cited by 26
Spotlight on GOT2 in Cancer Metabolism
Kerk, S. A., García‐Bermúdez, J., Birsoy, K., Sherman, M. H., Shah, Y. M., & Lyssiotis, C. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s382161 · Cited by 27
Self-citationTumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Laubach, K., Turan, T., Mathew, R. S., Wilsbacher, J. L., Engelhardt, J., & Samayoa, J. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.60 · Cited by 27
Critical roles and clinical perspectives of RNA methylation in cancer
Li, G., Yao, Q., Liu, P., Zhang, H., Liu, Y., Li, S., Shi, Y., Li, Z., & Zhu, W. (2024) · MedComm · doi:10.1002/mco2.559 · Cited by 29
Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis
Tassone, B., Saoncella, S., Neri, F., Ala, U., Brusa, D., Magnuson, M. A., Provero, P., Oliviero, S., Riganti, C., & Calautti, E. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.8 · Cited by 26
The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension
Bertero, T., Perk, D., & Chan, S. Y. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1615438 · Cited by 26
Solsona, B. G., Horn, H., Schmitt, A., Xu, W., Bucher, P., Heinrich, A., Kalmbach, S., Kreienkamp, N., Franke, M., Wimmers, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010964 · Cited by 26
Androgens drive SLC1A5-dependent metabolic reprogramming in polycystic ovary syndrome
Wang, Y., Wu, J., Zhang, G., Shi, Y., Meng, Y., Lv, P., Huang, W., Su, Y., Zhou, Z., Wang, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62951-z · Cited by 28
Self-citationMöller, J., Bhat, K., Riecken, K., Pörtner, R., Zeng, A., & Jandt, U. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27124 · Cited by 25
Chen, D., Hu, G., Zhang, S., Zhang, H., & Teng, X. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110619 · Cited by 25
The Role of Host-Generated H2S in Microbial Pathogenesis: New Perspectives on Tuberculosis
Rahman, M. A., Glasgow, J. N., Nadeem, S., Reddy, V. P., Sevalkar, R. R., Lancaster, J. R., & Steyn, A. J. C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.586923 · Cited by 25
Plangger, A., Rath, B., Hochmair, M. J., Funovics, M. A., & Hamilton, G. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101230 · Cited by 24
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches
Gómez-Cebrián, N., Poveda, J. L., Pineda‐Lucena, A., & Puchades‐Carrasco, L. (2022) · Cancers · doi:10.3390/cancers14030596 · Cited by 27
Li, S., & Xie, K. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188698 · Cited by 27
The Role of Glutamine and Glutaminase in Pulmonary Hypertension
Wang, S., Yan, Y., Xu, W., Gong, S., Zhong, X.-J., An, Q.-Y., Zhao, Y., Liu, J., Wang, L., Yuan, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.838657 · Cited by 25
Eskandari, R., Kim, N., Mamakhanyan, A., Saoi, M., Zhang, G., Berishaj, M., Granlund, K. L., Poot, A. J., Cross, J. R., Thompson, C. B., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120595119 · Cited by 25
Roh, J., Im, M., Chae, Y., Kang, J., & Kim, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314808 · Cited by 25
Bandi, D. S. R., Sarvesh, S., Farran, B., Nagaraju, G. P., & El‐Rayes, B. F. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.06.006 · Cited by 26
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
Metadata
- Authors
- Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Corresponding author
- Cantley, Lewis C.
- Kimmelman, Alec C.
- ORCID
- Venue
- Nature
- Published
- 2013-03-27
- Volume
- 496
- Issue
- 7443
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656466
- OpenAlex
- W2014988241
- Cited by
- 1,990
- References
- 27
- Citations by year
- 2026: 130 · 2025: 143 · 2024: 138 · 2023: 169 · 2022: 193 · 2021: 209 · 2020: 169 · 2019: 162 · 2018: 141 · 2017: 144 · 2016: 152 · 2015: 112 · 2014: 95 · 2013: 31
- FWCI
- 45.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009382, R01CA157490, P01CA120964, P01CA117969, P30CA006516)
- National Institute of General Medical Sciences (R01GM056203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, glutamine metabolism, KRAS, tumor metabolic reprogramming, oxaloacetate, NADPH/NADP+ ratio, redox homeostasis, glutamine deprivation, reactive oxygen species, glutathione, tumor growth
- MeSH terms
- Adenocarcinoma, Aspartate Aminotransferases, Citric Acid Cycle, Glutamate Dehydrogenase, Glutamine, Homeostasis, Humans, Ketoglutaric Acids, Oncogenes, Oxidation-Reduction, Pancreatic Neoplasms, Proto-Oncogene Proteins, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Reactive Oxygen Species, ras Proteins, Cell Line, Tumor, Cell Proliferation, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
